Japan, Feb. 24 -- TRANSLATE BIO INC has got intellectual property rights for 'MRNA THERAPY FOR ARGINOSUCCINATE SYNTHETASE DEFICIENCY.' Other related details are as follows:
Application Number: JP,2021-212128
Category (FI): A61K47/24,C12N15/52@Z,C12N15/12,A61K38/43,A61K47/22,A61K47/28,A61K9/127,A61P43/00,111,A61P3/00,A61K48/00
Stage: PROBLEM TO BE SOLVED: To provide improved methods and compositions for treating arginosuccinate deficiency (ASD) based on mRNA therapy.SOLUTION: The invention provides methods and compositions for treating arginosuccinate synthetase deficiency (ASD) based on mRNA therapy. More specifically, the invention provides a method for treating ASD by administering to a subject in need of treatment a composition compri...